Interview With Christi Myers

MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#mindmed #mmed #mnmdstock

Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode.

Timestamps:
0:00 – Intro
0:18 – FDA clears researchers to test MDMA on themselves
1:55 – MindMed (MMED / MNMD) announces Q1 Financials
4:30 – Compass Pathways (CMPS) announces Q1 Financials
6:56 – Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health
8:17 – Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’
9:31 – Wesana Health Holdings (WESA) begins trading on the CSE

Link to the FDA clearing researchers to test MDMA on themselves:
https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/

Link to Mindmed’s Q1 2021 Financial report and business highlights:
https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html

Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html

Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health:
https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application

Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’:
https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/

Link to Wesana Health Holdings (WESA):
https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse

Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPS

MindMed (Nasdaq:MNMD, NEO:MMED) has launched recruitment for their phase 2a clinical trial, testing using LSD microdoses to treat Adult ADHD!
MindMed’s stock has been down a lot recently, which has people asking “should I sell MindMed”, or “Is MindMed stock a good investment?”, or “why is MindMed stock down?”.

A lot of this drop has to do with a lack of news, not bad news. Now, at long last we finally have some good news! I have been looking forward to this trial starting for over a year now!

This LSD microdosing study is part of Project Flow, MindMed’s LSD microdosing division.

Microdosing LSD, anecdotally, has been shown to: increase focus; decrease anxiety; increase creativity; and improve mood. As improving focus and decreasing anxiety are two issues individuals with ADHD often need help with, it is possible that this may be a better medication than stimulants like Adderall.

The 52 person, placebo controlled study will give 20 micrograms of LSD to Adult ADHD sufferers twice a week for 6 weeks. Six weeks after treatment, the patients symptoms will be compared to where they were before the trial, and compared against the placebo group.

If they do show significant improvement, it will be the first scientific evidence that LSD microdoses can help treat adult ADHD.
Not only would this help tens of millions of people, it would also be lucrative for MindMed, as in the USA alone, the ADHD treatment market is valued at $12.9 billion annually.

Is LSD microdosing good for you? Can LSD Microdosing improve your mental health and Creativity? MindMed aims to find out!

References:

Press Release
https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html

MindMed Investor’s Deck
https://mindmed.co/wp-content/uploads/2021/12/MindMed-Presentation-December-2021.pdf

New CEO
https://www.newswire.ca/news-releases/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-879570624.html

Microdosing study 1
https://pubmed.ncbi.nlm.nih.gov/34795334/

Microdosing study 2
https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy
@Psychedelic Spotlight

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Microdosing #ADHD